Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Costs and Expenses:
General and administrative	$ 1,419,000	$ 1,393,000
Research and development	1,118,000	1,635,000
Total Operating Costs and Expenses	2,537,000	3,028,000
Loss from Operations	(2,537,000)	(3,028,000)
Other Income :
Interest income	0	38,000
Total Other Income	0	38,000
Net Loss	(2,537,000)	(2,990,000)
Net Loss Attributable to Non-controlling Interest	(1,000)	(26,000)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(2,536,000)	(2,964,000)
Effect of Series A Preferred Stock Price adjustment	(7,402,000)	0
Net Loss Attributable to Common Stockholders	$ (11,459,000)	$ (3,430,000)
Net Loss Per Share - Basic and Dilutive	$ (0.13)	$ (0.20)
Weighted average number of shares outstanding during the period - Basic and Dilutive	90,807,693	17,093,920
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (24,000)	$ (62,000)
Effect of Series A Preferred Stock Price adjustment	7,402,000
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (1,497,000)	$ (404,000)